TABLE 2.
Favorable Outcome at Time of Discharge, Overall and by Cause of Stroke*
| Sulfonylurea (N=33) | Control (N=28) | P Value | |
|---|---|---|---|
| NIHSS improvement ≥4 or NIHSS=0 | 36.4 (12) | 7.1 (2) | 0.007† |
| Lacunar stroke | 14.3 (1/7) | 15.4 (2/13) | 0.032‡ |
| Nonlacunar stroke§ | 42.3 (11/26) | 0.0 (0/15) | |
| mRS ≤2 | 81.8 (27) | 57.1 (16) | 0.035† |
| Lacunar stroke | 71.4 (5/7) | 69.2 (9/13) | 0.17‡ |
| Nonlacunar stroke∥ | 84.6 (22/26) | 46.7 (7/15) |
Values indicate percent of the group (no. of patients).
P value computed from Pearson's χ2 test comparing 2 groups.
P value corresponding to test of interaction between cause of stroke and group.
Includes large-artery atherosclerosis (7 of 13), cardioembolic (one of 6), and other/undetermined (3 of 7) in the sulfonylurea group; and large-artery atherosclerosis (zero of 11), cardioembolic (zero of 3), and other/undetermined (zero of one) in the control group.
Includes large-artery atherosclerosis (13 of 13), cardioembolic (5 of 6), and other/undetermined (4 of 7) in the sulfonylurea group; and large-artery atherosclerosis (5 of 11), cardioembolic (one of 3), and other/undetermined (one of one) in the control group.